(Q43779548)

26 November 2017

Low-dose low-molecular weight heparin (enoxaparin) is effective as adjuvant treatment in active ulcerative colitis: an open trial (English)

1 reference

26 November 2017

1 reference

Dotan I

1

1 reference

26 November 2017

Hallak A

2

1 reference

26 November 2017

Arber N

3

1 reference

26 November 2017

Santo M

4

1 reference

26 November 2017

Alexandrowitz A

5

1 reference

26 November 2017

Knaani Y

6

1 reference

26 November 2017

Hershkoviz R

7

1 reference

26 November 2017

Brazowski E

8

1 reference

26 November 2017

Halpern Z

9

1 reference

26 November 2017

1 October 2001

1 reference

Digestive Diseases and Sciences

26 November 2017

1 reference

26 November 2017

46

1 reference

26 November 2017

10

1 reference

26 November 2017

2239-2244

1 reference

https://scigraph.springernature.com/pub.10.1023/a:1011979418914

26 November 2017

0 references

cites work

Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor

1 reference

12 December 2020

Effect of heparin, dermatan sulfate, and related oligo-derivatives on human polymorphonuclear leukocyte functions

1 reference

12 December 2020

Pharmacology and special clinical applications of low-molecular-weight heparins.

1 reference

12 December 2020

Activated T lymphocytes produce a matrix-degrading heparan sulphate endoglycosidase

1 reference

12 December 2020

A disaccharide that inhibits tumor necrosis factor alpha is formed from the extracellular matrix by the enzyme heparanase

1 reference

12 December 2020

Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group

1 reference

12 December 2020

Heparin disaccharides inhibit tumor necrosis factor-alpha production by macrophages and arrest immune inflammation in rodents

1 reference

12 December 2020

Paradoxical response to heparin in 10 patients with ulcerative colitis

1 reference

12 December 2020

Inhibition of heparanase-mediated degradation of extracellular matrix heparan sulfate by non-anticoagulant heparin species

1 reference

12 December 2020

Low-dose low-molecular-weight heparin (enoxaparin) is beneficial in lichen planus: a preliminary report

1 reference

12 December 2020

Serum basic fibroblast growth factor in pediatric Crohn's disease. Implications for wound healing.

1 reference

12 December 2020

Anti-inflammatory properties of unfractioned heparin in patients with highly active ulcerative colitis: a pilot study

1 reference

12 December 2020

A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis

1 reference

12 December 2020

Degradation of heparan sulfate in the subendothelial extracellular matrix by a readily released heparanase from human neutrophils. Possible role in invasion through basement membranes

1 reference

12 December 2020

Heparin, cell adhesion, and pathogenesis of inflammatory bowel disease

1 reference

12 December 2020

Evaluation of the effects of low molecular weight heparin on inflammation and collagen deposition in chronic coxsackievirus B3-induced myocarditis in A/J mice

1 reference

12 December 2020

Unfractioned heparin in the therapy of patients with highly active inflammatory bowel disease

1 reference

12 December 2020

Expression of syndecan-1 in inflammatory bowel disease and a possible mechanism of heparin therapy

1 reference

12 December 2020

Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation

1 reference

12 December 2020

Suppression of syndecan-1 expression in endothelial cells by tumor necrosis factor-alpha.

1 reference

12 December 2020

On the binding of tumor necrosis factor (TNF) to heparin and the release in vivo of the TNF-binding protein I by heparin

1 reference

12 December 2020

Pathogenesis of Crohn's disease: multifocal gastrointestinal infarction

1 reference

12 December 2020

The effect of heparin on trinitrobenzene sulphonic acid-induced colitis in the rat

1 reference

12 December 2020

Inflammatory bowel disease

1 reference

12 December 2020

Low molecular weight heparin as adjuvant therapy in active ulcerative colitis

1 reference

12 December 2020

Coagulation studies in ulcerative colitis and Crohn's disease

1 reference

12 December 2020

'Sticky' neutrophils, pathergic arthritis, and response to heparin in pyoderma gangrenosum complicating ulcerative colitis

1 reference

12 December 2020

Treatment of concanavalin A-induced hepatitis in mice with low molecular weight heparin

1 reference

12 December 2020

Low doses of low molecular weight heparin in vivo inhibits the elicitation of contact hypersensitivity.

1 reference

12 December 2020

Indium 111-granulocyte scanning in the assessment of disease extent and disease activity in inflammatory bowel disease. A comparison with colonoscopy, histology, and fecal indium 111-granulocyte excretion

1 reference

12 December 2020

Risk of thromboembolic complications in patients with inflammatory bowel disease. Study of hemostasis measurements

1 reference

12 December 2020

Therapeutic uses of heparin beyond its traditional role as an anticoagulant.

1 reference

12 December 2020

Identifiers

DOI

10.1023/A:1011979418914

1 reference

Dimensions Publication ID

26 November 2017

0 references

1 reference